An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies with HRAS Mutations
Phase of Trial: Phase II
Latest Information Update: 21 May 2018
At a glance
- Drugs Tipifarnib (Primary)
- Indications Head and neck cancer; Solid tumours; Squamous cell cancer; Thyroid cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms RUN-HN
- Sponsors Kura Oncology
- 12 Mar 2018 According to a Kura Oncology media release, additional updates from this trial is expected in the second half of 2018.
- 15 Feb 2018 According to a Kura Oncology media release, nine patients had been enrolled as of the February 8, 2018 data cutoff date.
- 15 Feb 2018 Preliminary results (n=6), as of February 8, 2018 data cutoff date, published in a Kura Oncology Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History